Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem

Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem

Abstract Background Ceftolozane/tazobactam, a combination antibacterial agent comprising an anti-pseudomonal cephalosporin and β-lactamase inhibitor, is approved for the treatment of hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP) in adults. Participants in the ASPECT-NP tria...

Full description

Bibliographic Details
Main Authors: Marin H. Kollef, Jean-François Timsit, Ignacio Martin-Loeches, Richard G. Wunderink, Jennifer A. Huntington, Erin H. Jensen, Brian Yu, Christopher J. Bruno
Format: Article
Language:English
Published: BMC 2022-12-01
Series:Critical Care
Subjects:
Nosocomial pneumonia
HABP
VABP
Mechanical ventilation
All-cause mortality
Clinical response
Online Access:https://doi.org/10.1186/s13054-022-04192-w

Internet

https://doi.org/10.1186/s13054-022-04192-w

Similar Items